Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05890781

Engineering Immune Organoids to Study Pediatric Cancer

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Brain Tumor Adenocarcinoma Brain Diseases Brain Neoplasms Carcinoma Carcinoma, Renal Cell Central Nervous System Diseases Central Nervous System Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Kidney Tumor Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nervous System Diseases Nervous System Neoplasms Neuroblastoma Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Sarcoma Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

Up to 25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Necker, Paris, Île-de-France Region, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
  • Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
  • Brain tumors
  • Renal tumors
  • Neuroblastoma
  • Sarcomas
  • Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  • Affiliated to a social security system or beneficiary of the same.

Exclusion criteria

  • Any histology not mentioned in the inclusion criteria
  • Adult patient or parents/guardians incapable/incapable of giving its/their consent
  • Patients deprived of their liberty by a judicial or administrative decision

Treatment and study plan

skin biopsy

Procedure

Skin biopsy

Fresh tumor sample

Procedure

Fresh tumor sample

Blood sample

Biological

Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

Healthy tissue from the tumor

Procedure

Healthy tissue from the tumor site whenever possible

Spinal cerebrospinal fluid (SCF)

Procedure

Spinal cerebrospinal fluid (SCF) whenever possible

Primary outcomes

  1. Proportion of viable and exploitable immune organoids with engrafted tumor cells

    Time frame: until 5 years after enrolment

Study contacts

Contact information is provided by the study sponsor or research team.

Claudia PASQUALINI, MD

CONTACT

[email protected]

+33 (0)1 42 11 55 31

Jérémy MIONE, MS

CONTACT

[email protected]

+33 (0)1 42 11 42 11 ext. 38 61

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Official study title

Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)

Acronym: IMMUNEORGANOID

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Jun 6, 2023
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.